## **EXHIBIT E**

Case 8:15-cv-00<del>992-JAK-PL</del> Page 2 of 2 Page ID #:40 Ocument Export Data Import Data Reset Form

## DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## APPLICATION TO MARKET A NEW OR ABBREVIATED NEW DRUG OR BIOLOGIC FOR HUMAN USE

Form Approved: OMB No. 0910-0338 Expiration Date: December 31, 2017 See PRA Statement on page 3.

1. Date of Submission (mm/dd/yyyy)

| (Title 21, Code of  | ⊢eaerai i | Regulatio                                      | ns, Parts 3            | 114 & 601)  | 03/XX/2015  |
|---|-----------|--|------------------------|---|---|
| APPLICANT INFORMATION   |           | 2. Name of Applicant Ferrum Ferro Capital, LLC |                        |   |   |
| 3 Telephone Number (Include country   |           |  |                        | I   |   |
| 3. Telephone Number (Include country code if applicable and area code) 1.302.514.0050   |           |  | d area code)           | 4. Facsimile (FAX) Number (Include country code if applicable and area code) 1.509.351.7892 |   |
| 5. Applicant Address  |           |  |                        |   |   |
| Address 1 (Street address, P.O. box, company name c/o) 717 N. Union Street, #78   |           |  |                        |   | Email Address   |
| Address 2 (Apartment, suite, unit, building, floor, etc.)   |           |  |                        |   | kb@ferrumferro.com  |
| City  |           | State/Pro                                      | ovince/Region          | )   | U.S. License Number if previously issued                      |
| Wilmington DE   |           |  |                        |   |   |
| Country United States of America  |           |  | ZIP or Pos<br>19805-30 |   |   |
| 6. Authorized U.S. Agent (Required for non-U.S. applicants)   |           |  |                        |   |   |
| Authorized U.S. Agent Name  |           |  |                        |   | Telephone Number (Include area code)                          |
| Address 1 (Street address, P.O. box, company name c/o)  |           |  |                        |   |   |
| Address 2 (Apartment, suite, unit, building, floor, etc.)   |           |  |                        |   | FAX Number (Include area code)                                |
| City  |           | State  |                        |   | Email Address   |
| ZIP Code  |           |  |                        |   |   |
| PRODUCT DESCRIPTION 7. NDA, ANDA, or BLA Application Number 8. Supplement Number (If applicable)  |           |  |                        |   |   |
| 7. NDA, ANDA, or BLA Application Number 8. Supplement Number (If applicable)  |           |  |                        |   |   |
| 9. Established Name (e.g., proper name, USP/USAN name)  |           |  |                        |   |   |
| Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution  |           |  |                        |   |   |
| 10. Proprietary Name (Trade Name) (If any) Combivious   |           |  |                        |   |   |
| 11. Chemical/Biochemical/Blood Product Name (If any)  |           |  |                        |   |   |
|   |           |  |                        |   |   |
| 12. Dosage Form Solution/Drops  |           | 13. Streng                                     |                        |   | 14. Route of Administration                                   |
| 15. Proposed Indication for Use   | L         | 0.2%;EQ (                                      | 0.5% Base              |   | Opthalmic   |
| Combivious (brimonidine tartrets/timolol maleate ophthalmic solution) 0.2%/0.5% will be an alpha-adrenergic receptor agonist with a beta-adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure  Does this product have an FDA If yes, provide the Orphan |           |  |                        |   |   |
| (IOP) in patients with glaucoma or ocular hypertensior<br>or replacement therapy due to inadequately controlled   |           |  |                        |   | Designation number for this indication:  Contin. Page for #15 |
| APPLICATION INFORMATION   |           | pplication 7                                   |                        | New Drug Application  | (NDA) Biologics License Application (BLA)                     |
| (Select one)  Abbreviated New Drug Application (ANDA)   |           |  |                        |   |   |
| 17. If an NDA, identify the type  |           |  |                        |   |   |
| 19. If a 351(k), identify the biological reference product that is the basis for the submission.  Name of Biologic: Holder of Licensed Application:   |           |  |                        |   |   |
| 20. If an ANDA, or 505(b)(2), identify the listed drug product that is the basis for the submission.  |           |  |                        |   |   |
| Name of Drug: Combigan Application Number of Relied Upon Product: N021398   |           |  |                        |   |   |
| Indicate Patent Certification(s): P1 P2 P3 P4 Section viii - MOU Statement of no relevant patents   |           |  |                        |   |   |
| 21. Submission (Select one) 🔽 Original 🔲 Labeling Supplement 🔲 CMC Supplement 🔲 Efficacy Supplement 🔲 Annual Report   |           |  |                        |   |   |
| Product Correspondence  |           | upplement                                      | _                      | narketing Requirement   |   |
| Other (Specify):  |           |  |                        |   |   |

FORM FDA 356h (12/14)